Clinical Trial Update: A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF) [Phase 2]

View source ↗

Summary

A Phase IIb study evaluating intravenous Cinaciguat in patients with acute decompensated heart failure was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure
• Heart Failure

Drugs mentioned

• Cinaciguat (cinaciguat)

Snippet

Sponsor: Bayer | Conditions: Heart Failure, Heart Decompensation | Phase 2 | Status: TERMINATED